Oral antithrombotic use among myocardial infarction patientsVAN DER ELST, Menno E; CISNEROS-GONZALEZ, Nelly; DE BLAEY, Cornelis J et al.The Annals of pharmacotherapy. 2003, Vol 37, Num 1, pp 143-146, issn 1060-0280, 4 p.Article

National Trends in Oral Anticoagulant Use in the United States, 2007 to 2011KIRLEY, Kate; QATO, Dima M; KORNFIELD, Rachel et al.Circulation. Cardiovascular quality and outcomes (Print). 2012, Vol 5, Num 5, pp 615-621, issn 1941-7713, 7 p.Article

Interaction of rofecoxib and celecoxib with warfarinSCHAEFER, Monica G; PLOWMAN, Brian K; MORREALE, Anthony P et al.American journal of health-system pharmacy. 2003, Vol 60, Num 13, pp 1319-1323, issn 1079-2082, 5 p.Conference Paper

Anticoagulation therapy in childrenREVEL-VILK, Shoshana; CHAN, Anthony K. C.Seminars in thrombosis and hemostasis. 2003, Vol 29, Num 4, pp 425-432, issn 0094-6176, 8 p.Article

Update on Antithrombotic Therapy New AnticoagulantsEIKELBOOM, John W; WEITZ, Jeffrey I.Circulation (New York, N.Y.). 2010, Vol 121, Num 13, pp 1523-1532, issn 0009-7322, 10 p.Article

Treatment with anticoagulants in cerebral events (TRACE)WOESSNER, Ralph; GRAUER, Markus; TREIB, Johannes et al.Thrombosis and haemostasis. 2004, Vol 91, Num 4, pp 690-693, issn 0340-6245, 4 p.Article

STANDARDIZING THE CONTROL OF ORAL ANTICOAGULANT TREATMENT. SYMPOSIUM. PART OF THE MEETING OF THE INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS, VIENNA; 1973.1975; THROMBOSIS DIATHESIS HAEMORRHAG.; ALLEM.; DA. 1975; VOL. 33; NO 2; PP. 142-171; ABS. FR. ALLEM.; BIBL. DISSEM.Conference Paper

Une tumeur axillaire douloureuse = A painful axillary tumorSENE, T; GONCALVES, C; TAGZIRT, M et al.La Revue de médecine interne (Paris). 2009, Vol 30, Num 11, pp 974-975, issn 0248-8663, 2 p.Article

Development in anticoagulant therapyVAN DOORMAAL, F. F; BÜLLER, H. R; MIDDELDORP, S et al.Critical reviews in oncology/hematology. 2008, Vol 66, Num 2, pp 145-154, issn 1040-8428, 10 p.Article

Prescription des anticoagulants chez le sujet âgé : éléments de la décision thérapeutique. Exemple de la maladie veineuse thromboembolique (MVTE) = Anticoagulating treatment in aging patients: elements of therapeutic decision. Exemple of thromboembolic diseaseMOTTIER, Dominique; LACUT, Karine.MT. Médecine thérapeutique. 2003, Vol 9, Num 1-2, pp 7-11, issn 1264-6520, 5 p.Article

Optimal initial dose adjustment of warfarin in orthopedic patientsLENZINI, Petra A; GRICE, Gloria R; GAGE, Brian F et al.The Annals of pharmacotherapy. 2007, Vol 41, Num 11, pp 1798-1804, issn 1060-0280, 7 p.Article

Isolation and Purification of an Anticoagulant from Schizymenia dubyi by FermentationEKANAYAKE, P. M; NIKAPITIYA, C; DE ZOYSA, M et al.Food science and technology international. 2007, Vol 13, Num 5, pp 355-359, issn 1082-0132, 5 p.Article

Laboratory analysis of blood samples from patients treated with tinzaparinHOPPENSTEADT, Debra A; WILLOWS, Louise; LEITZ, Helen et al.Seminars in thrombosis and hemostasis. 2004, Vol 30, pp 49-55, issn 0094-6176, 7 p., SUP1Conference Paper

Identifying Major Hemorrhage with Automated Data: Results of the Veterans Affairs Study to Improve Anticoagulation (VARIA)JASUJA, Guneet K; REISMAN, Joel I; MILLER, Donald R et al.Thrombosis research. 2013, Vol 131, Num 1, pp 31-36, issn 0049-3848, 6 p.Article

Assays for Measuring Rivaroxaban: Their Suitability and LimitationsLINDHOFF-LAST, Edelgard; SAMAMA, Meyer Michel; ORTEL, Thomas L et al.Therapeutic drug monitoring. 2010, Vol 32, Num 6, pp 673-679, issn 0163-4356, 7 p.Article

Improved Oral Anticoagulation After a Dietary Vitamin K―Guided Strategy: A Randomized Controlled TrialDE ASSIS, Michelli C; RABELO, Eneida R; AVILA, Christiane W et al.Circulation (New York, N.Y.). 2009, Vol 120, Num 12, pp 1115-1122, issn 0009-7322, 8 p.Article

The duration of oral anticoagulation after deep vein thrombosis: a randomized studySCHULMAN, S; LOCKNER, D; JUHLIN-DANNFELT, A et al.Acta medica Scandinavica. 1985, Vol 217, Num 5, pp 547-552, issn 0001-6101Article

Inhibition by warfarin of liver microsomal vitamin K-reductase in warfarin-resistant and susceptible ratsMACNICOLL, A. D; NADIAN, A. K; TOWNSEND, M. G et al.Biochemical pharmacology. 1984, Vol 33, Num 8, pp 1331-1336, issn 0006-2952Article

Actualités sur les héparines = New about heparinsBONEU, B.Nouvelle revue de médecine de Toulouse. Supplément. 1984, Vol 2, Num 8, pp 406-407, issn 0753-4515Article

What can we learn from the three megatrials using anticoagulants in severe sepsis?IBA, Toshiaki; KIDOKORO, Akio.Shock (Augusta, Ga.). 2004, Vol 22, Num 6, pp 508-512, issn 1073-2322, 5 p.Article

Analysis of the mechanism of the magnesium effect on the warfarin-albumin interactionVAN DER GIESEN, W. F; WILTING, J.Biochemical pharmacology. 1984, Vol 33, Num 10, pp 1679-1681, issn 0006-2952Article

Avulsions dentaires et anticoagulants = Dental extraction and anti-coagulantsPERSAC, S; BOLAND, F.-X; LAVIS, J.-F et al.Revue de stomatologie et de chirurgie maxillo-faciale. 2007, Vol 108, Num 3, pp 189-192, issn 0035-1768, 4 p.Article

Immunoassay and antibody microarray analysis of the HUPO Plasma Proteome Project reference specimens : Systematic variation between sample types and calibration of mass spectrometry dataHAAB, Brian B; GEIERSTANGER, Bernhard H; SURESH, Shubha et al.Proteomics (Weinheim. Print). 2005, Vol 5, Num 13, pp 3278-3291, issn 1615-9853, 14 p.Article

Interaction of warfarin with human serum albumin: a stoichiometric descriptionLARSEN, F. G; LARSEN, C. G; JAKOBSEN, P et al.Molecular pharmacology. 1985, Vol 27, Num 2, pp 263-270, issn 0026-895XArticle

Utilité de la surveillance biologique de l'héparinothérapie à visée curative = Usefulness of a biological supervision during curative heparinotherapyDEMICHELIS, C; COHEN, S; BRAGUER, D et al.Journal de pharmacie clinique (Paris). 1984, Vol 3, Num 3-4, pp 367-373, issn 0291-1981Article